506 related articles for article (PubMed ID: 30196789)
1. The AtRial Cardiopathy and Antithrombotic Drugs In prevention After cryptogenic stroke randomized trial: Rationale and methods.
Kamel H; Longstreth WT; Tirschwell DL; Kronmal RA; Broderick JP; Palesch YY; Meinzer C; Dillon C; Ewing I; Spilker JA; Di Tullio MR; Hod EA; Soliman EZ; Chaturvedi S; Moy CS; Janis S; Elkind MS
Int J Stroke; 2019 Feb; 14(2):207-214. PubMed ID: 30196789
[TBL] [Abstract][Full Text] [Related]
2. Apixaban to Prevent Recurrence After Cryptogenic Stroke in Patients With Atrial Cardiopathy: The ARCADIA Randomized Clinical Trial.
Kamel H; Longstreth WT; Tirschwell DL; Kronmal RA; Marshall RS; Broderick JP; Aragón García R; Plummer P; Sabagha N; Pauls Q; Cassarly C; Dillon CR; Di Tullio MR; Hod EA; Soliman EZ; Gladstone DJ; Healey JS; Sharma M; Chaturvedi S; Janis LS; Krishnaiah B; Nahab F; Kasner SE; Stanton RJ; Kleindorfer DO; Starr M; Winder TR; Clark WM; Miller BR; Elkind MSV;
JAMA; 2024 Feb; 331(7):573-581. PubMed ID: 38324415
[TBL] [Abstract][Full Text] [Related]
3. Apixaban for treatment of embolic stroke of undetermined source (ATTICUS randomized trial): Rationale and study design.
Geisler T; Poli S; Meisner C; Schreieck J; Zuern CS; Nägele T; Brachmann J; Jung W; Gahn G; Schmid E; Bäezner H; Keller T; Petzold GC; Schrickel JW; Liman J; Wachter R; Schön F; Schabet M; Lindner A; Ludolph AC; Kimmig H; Jander S; Schlegel U; Gawaz M; Ziemann U
Int J Stroke; 2017 Dec; 12(9):985-990. PubMed ID: 27881833
[TBL] [Abstract][Full Text] [Related]
4. Apixaban versus Antiplatelet drugs or no antithrombotic drugs after anticoagulation-associated intraCerebral HaEmorrhage in patients with Atrial Fibrillation (APACHE-AF): study protocol for a randomised controlled trial.
van Nieuwenhuizen KM; van der Worp HB; Algra A; Kappelle LJ; Rinkel GJ; van Gelder IC; Schutgens RE; Klijn CJ;
Trials; 2015 Sep; 16():393. PubMed ID: 26340977
[TBL] [Abstract][Full Text] [Related]
5. Atrial Cardiopathy and Cryptogenic Stroke: A Cross-sectional Pilot Study.
Yaghi S; Boehme AK; Hazan R; Hod EA; Canaan A; Andrews HF; Kamel H; Marshall RS; Elkind MS
J Stroke Cerebrovasc Dis; 2016 Jan; 25(1):110-4. PubMed ID: 26476588
[TBL] [Abstract][Full Text] [Related]
6. In cryptogenic stroke and atrial cardiopathy, apixaban did not reduce recurrent stroke vs. aspirin.
Field TS
Ann Intern Med; 2024 Jun; 177(6):JC65. PubMed ID: 38830225
[TBL] [Abstract][Full Text] [Related]
7. Apixaban versus aspirin in patients with atrial fibrillation and previous stroke or transient ischaemic attack: a predefined subgroup analysis from AVERROES, a randomised trial.
Diener HC; Eikelboom J; Connolly SJ; Joyner CD; Hart RG; Lip GY; O'Donnell M; Hohnloser SH; Hankey GJ; Shestakovska O; Yusuf S;
Lancet Neurol; 2012 Mar; 11(3):225-31. PubMed ID: 22305462
[TBL] [Abstract][Full Text] [Related]
8. Novel oral anticoagulants for stroke prevention in atrial fibrillation: focus on apixaban.
Potpara TS; Polovina MM; Licina MM; Stojanovic RM; Prostran MS; Lip GY
Adv Ther; 2012 Jun; 29(6):491-507. PubMed ID: 22684583
[TBL] [Abstract][Full Text] [Related]
9. Stroke risk and efficacy of apixaban in atrial fibrillation patients with moderate chronic kidney disease.
Eikelboom JW; Connolly SJ; Gao P; Paolasso E; De Caterina R; Husted S; O'Donnell M; Yusuf S; Hart RG
J Stroke Cerebrovasc Dis; 2012 Aug; 21(6):429-35. PubMed ID: 22818021
[TBL] [Abstract][Full Text] [Related]
10. Secondary Stroke Prevention Following Embolic Stroke of Unknown Source in the Absence of Documented Atrial Fibrillation: A Clinical Review.
Kotadia ID; Sim I; Mukherjee R; O'Hare D; Chiribiri A; Birns J; Bhalla A; O'Neill M; Williams SE
J Am Heart Assoc; 2021 Jul; 10(13):e021045. PubMed ID: 34212774
[TBL] [Abstract][Full Text] [Related]
11. Distribution of atrial cardiomyopathy markers and association with atrial fibrillation detected after ischaemic stroke in the SAFAS study.
Didier R; Garnier L; Duloquin G; Meloux A; Sagnard A; Graber M; Dogon G; Benali K; Pommier T; Laurent G; Vergely C; Bejot Y; Guenancia C
Stroke Vasc Neurol; 2024 Apr; 9(2):165-173. PubMed ID: 37429637
[TBL] [Abstract][Full Text] [Related]
12. Cryptogenic Stroke: Diagnostic Workup and Management.
Mac Grory B; Flood SP; Apostolidou E; Yaghi S
Curr Treat Options Cardiovasc Med; 2019 Dec; 21(11):77. PubMed ID: 31792625
[TBL] [Abstract][Full Text] [Related]
13. Modification of outcomes with aspirin or apixaban in relation to CHADS(2) and CHA(2)DS(2)-VASc scores in patients with atrial fibrillation: a secondary analysis of the AVERROES study.
Lip GY; Connolly S; Yusuf S; Shestakovska O; Flaker G; Hart R; Lanas F; Xavier D; Eikelboom J;
Circ Arrhythm Electrophysiol; 2013 Feb; 6(1):31-8. PubMed ID: 23390125
[TBL] [Abstract][Full Text] [Related]
14. Clinical outcomes in patients with atrial fibrillation according to sex during anticoagulation with apixaban or warfarin: a secondary analysis of a randomized controlled trial.
Vinereanu D; Stevens SR; Alexander JH; Al-Khatib SM; Avezum A; Bahit MC; Granger CB; Lopes RD; Halvorsen S; Hanna M; Husted S; Hylek EM; Mărgulescu AD; Wallentin L; Atar D
Eur Heart J; 2015 Dec; 36(46):3268-75. PubMed ID: 26371113
[TBL] [Abstract][Full Text] [Related]
15. Design of Randomized, double-blind, Evaluation in secondary Stroke Prevention comparing the EfficaCy and safety of the oral Thrombin inhibitor dabigatran etexilate vs. acetylsalicylic acid in patients with Embolic Stroke of Undetermined Source (RE-SPECT ESUS).
Diener HC; Easton JD; Granger CB; Cronin L; Duffy C; Cotton D; Brueckmann M; Sacco RL;
Int J Stroke; 2015 Dec; 10(8):1309-12. PubMed ID: 26420134
[TBL] [Abstract][Full Text] [Related]
16. Atrial Cardiopathy and Cryptogenic Stroke.
Kato Y; Takahashi S
Front Neurol; 2022; 13():839398. PubMed ID: 35273560
[TBL] [Abstract][Full Text] [Related]
17. An open-Label, 2 × 2 factorial, randomized controlled trial to evaluate the safety of apixaban vs. vitamin K antagonist and aspirin vs. placebo in patients with atrial fibrillation and acute coronary syndrome and/or percutaneous coronary intervention: Rationale and design of the AUGUSTUS trial.
Lopes RD; Vora AN; Liaw D; Granger CB; Darius H; Goodman SG; Mehran R; Windecker S; Alexander JH
Am Heart J; 2018 Jun; 200():17-23. PubMed ID: 29898844
[TBL] [Abstract][Full Text] [Related]
18. Efficacy and safety of apixaban compared with warfarin according to patient risk of stroke and of bleeding in atrial fibrillation: a secondary analysis of a randomised controlled trial.
Lopes RD; Al-Khatib SM; Wallentin L; Yang H; Ansell J; Bahit MC; De Caterina R; Dorian P; Easton JD; Erol C; Ezekowitz JA; Gersh BJ; Granger CB; Hohnloser SH; Horowitz J; Hylek EM; McMurray JJ; Mohan P; Vinereanu D; Alexander JH
Lancet; 2012 Nov; 380(9855):1749-58. PubMed ID: 23036896
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of apixaban compared with aspirin for stroke prevention in atrial fibrillation among patients unsuitable for warfarin.
Lee S; Anglade MW; Meng J; Hagstrom K; Kluger J; Coleman CI
Circ Cardiovasc Qual Outcomes; 2012 Jul; 5(4):472-9. PubMed ID: 22740012
[TBL] [Abstract][Full Text] [Related]
20. Rationale and design of the SAFE-A study: SAFety and Effectiveness trial of Apixaban use in association with dual antiplatelet therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention.
Hoshi T; Sato A; Nogami A; Gosho M; Aonuma K;
J Cardiol; 2017 Apr; 69(4):648-651. PubMed ID: 27443596
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
